FIND DRUGS:

BRAND NAME GENERIC NAME INDICATION MANUFACTURERS COMPARE DRUGS

New Cancer Progress Report From AACR

A new report from the American Association for Cancer Research highlights the need for increased federal funding of cancer research.

Considerations for Primary ADT for Localized Prostate Cancer

Although ADT remains an important treatment, its use as primary therapy in low-risk prostate cancer seems increasingly ill advised.

CTA Social Media Survey

CTA would like to know how you use social media services to make sure we’re effectively delivering the content you love.

Neurofibromatosis Type 1 (NF-1) and Neoplasms

BYL719, an effective treatment in combination with cetuximab in patients with cetuximab-resistant head and neck cancer.

Is It Time to Reclassify Some Cancers?

1 in 10 patients with cancer would be more accurately diagnosed if their tumors were defined by cellular and molecular criteria.

Communicating with Patients with Cancer

Dr. Dizon and patient advocate Katherine O'Brien discuss the difficulty of communicating cancer and give advice on common miscommunications.

Biomarkers of HIV-associated Cancer

Biomarkers can provide great opportunities in the management of the most common HIV-associated malignancies, namely, Kaposi sarcoma, non-Hodgkin's lymphoma, and invasive cervical cancer.

ZYDELIG (idelalisib) for Relapsed Follicular B-cell Non-Hodgkin Lymphoma

This slideshow reviews drug information for ZYDELIG (idelalisib), indicated for relapsed follicular non-Hodgkin lymphoma.

Featured Videos

Viewpoints & Feature Articles

AACR Cancer Progress Report Urges Increased Congressional Funding for NCI and NIH Research Budgets

AACR Cancer Progress Report Urges Increased Congressional Funding for NCI and NIH Research Budgets

Newly released 2014 Cancer Progress Report from the American Association for Cancer Research highlights the need for increased federal funding of cancer research.

Genomic Research Indicates the Need for Cancer Reclassification

Genomic Research Indicates the Need for Cancer Reclassification

1 in 10 patients with cancer would be more accurately diagnosed if their tumors were defined by cellular and molecular criteria.

Breast Cancer Recurrence Reduced by NSAID Use in Overweight and Obese Women

Breast Cancer Recurrence Reduced by NSAID Use in Overweight and Obese Women

A retrospective study identifies a potential link between NSAID use and breast cancer recurrence and overweight and obese women.

PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy

PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy

Immunotherapeutic approaches to treating cancer have been evaluated during the last few decades with limited success.

Primary Androgen-Deprivation Therapy (ADT) for Localized Prostate Cancer: Potential for Harm May Outweigh Benefit in Low-Risk Disease

Primary Androgen-Deprivation Therapy (ADT) for Localized Prostate Cancer: Potential for Harm May Outweigh Benefit in Low-Risk Disease

Although ADT remains an important treatment, its use as primary therapy in low-risk prostate cancer seems increasingly ill advised.

Biomarkers of HIV-associated Cancer

Biomarkers of HIV-associated Cancer

Biomarkers can provide great opportunities in the management of the most common HIV-associated malignancies, namely, Kaposi sarcoma, non-Hodgkin's lymphoma, and invasive cervical cancer.



From Oncology Nurse Advisor

Sign Up for Free e-newsletters

CTA Community Poll

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs